Combined stimulation of nasal polyp fibroblasts with poly IC, interleukin 4, and tumor necrosis factor alpha potently induces production of thymus- and activation-regulated chemokine.
OBJECTIVE
To examine the effects of cytokines and poly IC on the expression of thymus- and activation-regulated chemokine (TARC), a potent chemoattractant for helper T-cell type 2 (T(H)2) cells, in nasal polyp fibroblasts.


METHODS
Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis.


METHODS
Academic research.


METHODS
Primary fibroblast lines were established from human nasal polyp biopsy tissue specimens (n = 5) removed at polypectomy.


METHODS
The expression of TARC messenger RNA (mRNA) was evaluated by real-time RT-PCR. The amount of TARC in the supernatants was measured by enzyme-linked immunosorbent assay.


RESULTS
Combined stimulation with interleukin 4 (IL-4) and tumor necrosis factor alpha (TNF-alpha) or with poly IC and IL-4 induced TARC production. Combined exposure of cells to poly IC, IL-4, and TNF-alpha resulted in substantial amounts of TARC release into the culture medium. Quantitative RT-PCR analysis revealed that simultaneous stimulation with those 3 compounds induced a tremendous increase in the amount of TARC mRNA in the nasal polyp fibroblasts.


CONCLUSIONS
Nasal polyp fibroblasts contribute to T(H)2 cell infiltration and RNA virus-induced exacerbation of T(H)2-type airway inflammatory conditions such as allergic chronic sinusitis.
Nonaka
Manabu
M
Department of Otolaryngology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. nonaka@nms.ac.jp
Ogihara
Nozomu
N
Fukumoto
Akira
A
Sakanushi
Atsuko
A
Pawankar
Ruby
R
Yagi
Toshiaki
T
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D002478:Cells, Cultured; D054414:Chemokine CCL17 / Q000096:biosynthesis*; D005347:Fibroblasts / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology; D009298:Nasal Polyps / Q000276:immunology*; D011070:Poly I-C / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000276:Adjuvants, Immunologic; C106230:CCL17 protein, human; D054414:Chemokine CCL17; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D011070:Poly I-C